Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Published:2010-03 Issue:9719 Volume:375 Page:998-1006
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Raal Frederick J,Santos Raul D,Blom Dirk J,Marais A David,Charng Min-Ji,Cromwell William C,Lachmann Robin H,Gaudet Daniel,Tan Ju L,Chasan-Taber Scott,Tribble Diane L,Flaim JoAnn D,Crooke Stanley T

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Familial hypercholesterolemia;Goldstein,2001

2. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment;Rader;J Clin Invest,2003

3. Efficacy and safety of ezetimibe co administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia;Gagne;Circulation,2002

4. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia;Sachais;J Clin Apher,2005

5. Recommendations for the use of LDL apheresis;Thompson;Atherosclerosis,2008

Cited by 800 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress in gene therapy for familial hypercholesterolemia treatment;iScience;2024-09

2. Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia;Circulation;2024-08-27

3. The art of healing hearts: Mastering advanced RNA therapeutic techniques to shape the evolution of cardiovascular medicine in biomedical science;Current Problems in Cardiology;2024-08

4. Xeno Nucleic Acids as Functional Materials: From Biophysical Properties to Application;Advanced Healthcare Materials;2024-07-22

5. RNA in cardiovascular disease: A new frontier of personalized medicine;Progress in Cardiovascular Diseases;2024-07